Royalty Pharma PLC RPRX
58.21
0.56
0.97%
as of 25 Sep
- Market cap
- $34.4B
- P/E
- 40.1×
Follow RPRX
Growth Flags
show if company had growth for consecutive years
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| 8.42% | 8.38% | 7.69% | 7.73% |
+8 more TTM periods Free account |
|
| 4.26% | 4.42% | 4.07% | 4.11% | ||
ROIC |
5.28% | 5.43% | 5.41% | 5.44% | |
Return on Tangible Assets |
4.69% | 4.74% | 4.51% | 4.50% | |
Average Days of Receivables |
4.53 | 4.11 | 4.50 | 4.49 | |
Free Cash Flow per Share |
2.94 | 2.74 | 5.79 | 7.95 | |
Free Cash Flow |
1,310.08 | 1,195.57 | 2,489.82 | 3,432.44 | |
Capital Expenditures |
(1,666.37) | (1,416.41) | — | 1,027.24 | |
Piotroski F-Score |
5.00 | 4.00 | 4.00 | 4.00 | |
| Other line items | |||||
Cash ROIC |
15.20% | 13.39% | 12.90% | 12.32% | |
Accounts Receivable Turnover |
85.65 | 95.15 | 84.52 | 87.35 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
9.41% | 18.08% | 19.01% | 17.11% | |
Selling, General and Administrative Expense of Revenue |
23.83% | 25.50% | 24.11% | 20.29% | |
Share Based Compensation of Revenue |
16.86% | 16.86% | 12.19% | 7.01% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
3.67 | 3.16 | 3.23 | 3.13 | |
Depreciation/Fixed assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex/Depreciation |
(46.64) | (39.29) | 0.00 | 35.35 | |
Revenue per Share |
5.70 | 5.59 | 5.53 | 5.44 | |
Operating CF per Share |
6.69 | 5.98 | 5.79 | 5.57 | |
Capex per Share |
(3.74) | (3.24) | 0.00 | 2.38 | |
Capex to Sales |
0.66 | 0.58 | 0.00 | (0.44) | |
Net Profit Margin |
32.02% | 33.86% | 32.42% | 32.68% |
Columns are period end dates